Chapter 21. Physiologically Based Pharmacokinetic (PBPK) Models in Cancer Risk Assessment

  1. Ching-Hung Hsu and
  2. Todd Stedeford
  1. Mathieu Valcke1 and
  2. Kannan Krishnan2

Published Online: 5 AUG 2010

DOI: 10.1002/9780470622728.ch21

Cancer Risk Assessment

Cancer Risk Assessment

How to Cite

Valcke, M. and Krishnan, K. (2010) Physiologically Based Pharmacokinetic (PBPK) Models in Cancer Risk Assessment, in Cancer Risk Assessment (eds C.-H. Hsu and T. Stedeford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470622728.ch21

Editor Information

  1. Health, Safety & Environment, Albemarle Corporation, Baton Rouge, Louisiana, USA

Author Information

  1. 1

    National Institute of Public Health of Québec, Montreal, Quebec, Canada

  2. 2

    Department of Environmental Health and Health at Work, University of Montréal, Montreal, Quebéc, Canada

Publication History

  1. Published Online: 5 AUG 2010
  2. Published Print: 6 JUL 2010

ISBN Information

Print ISBN: 9780470238226

Online ISBN: 9780470622728

SEARCH

Keywords:

  • physiologically based pharmacokinetic (PBPK) models - in cancer risk assessment;
  • uncertainty, sensitivity and variability analyses - in PBPK modeling;
  • PBPK models, to estimate dose metrics - in different subgroups of a given population, animal or human

Summary

This chapter contains sections titled:

  • Introduction

  • PBPK Modeling: Characteristics and Approaches

  • PBPK Models in Cancer Risk Assessment

  • PBPK Models in Cancer Risk Assessment: Case Studies

  • Concluding Remarks

  • References